Encompass Health heads into its July 31 Q2 earnings report with options traders turning meaningfully more bullish even as short sellers quietly add to positions.
The clearest signal is in the options market. Demand for calls has outpaced puts sharply, with the put/call ratio dropping to 0.73 — more than two standard deviations below its 20-day average of 0.96. That makes this one of the most call-heavy setups EHC has seen in the past year, a notable shift given the stock had been running above parity on puts through most of July. The backdrop supports the optimism: EHC has climbed 12% over the past month to $113.88, and recent earnings history shows a consistent pattern of positive one-day reactions — the last three prints each produced gains of between 1% and 6.6%. The borrow market adds no friction to either side. Availability is essentially unlimited at over 4,000% of short interest, and cost to borrow is negligible at 0.39%. Short interest has edged higher — up roughly 10% in a single session on July 24 to 3.6% of the free float — but at that level and with borrow this loose, it represents a modest positioning move rather than a conviction bearish stance.
The analyst community remains firmly in the bull camp, though the Street has moderated its ambition. Eleven buy-equivalent ratings underpin a consensus price target near $141, implying roughly 24% upside from current levels. That gap has narrowed considerably as the stock has re-rated higher through 2026; Barclays trimmed its target from $153 to $140 after the Q1 print in May while holding its Overweight. The bull case centers on Encompass Health's expanding Medicare Advantage payer mix — now around 16.5% of revenue versus under 10% in 2018 — and a track record of upward revenue guidance revisions. Bears point to execution risk around de novo facility openings, where staffing costs and construction timelines in a tight labor market could pressure margins and push EBITDA targets out of reach. The stock's P/E has re-rated up roughly 10% over the past 30 days to around 17.9x, which leaves less room for disappointment.
Institutional ownership reflects broad-based confidence rather than concentrated risk. BlackRock and T. Rowe Price together hold nearly 19% of shares, and both added to positions in the most recent reporting period. AllianceBernstein built a meaningful stake through May, adding over 750,000 shares. Insiders, by contrast, have been consistent net sellers — the CFO liquidated nearly $3 million of stock in May, and the Q1 pattern included coordinated small sales across several C-suite executives on February 27. The net insider position over 90 days is modestly positive in share terms but driven largely by compensation-related mechanics rather than open-market conviction buying.
The July 31 print will test whether EHC's revenue trajectory and MA payer mix progress can justify a multiple that has expanded materially on the back of a strong momentum run — and whether operating margins at newly opened facilities are tracking ahead of the skeptics' timeline.
See the live data behind this article on ORTEX.
Open EHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
